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Abstract
In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in general, with a
particular focus on adenoviruses. These serve as a model to elucidate how versatile viruses are, and how they can
be used to complement other cancer therapies to gain optimal patient benefits. Historical reports from over a
hundred years suggest treatment efficacy and safety with adenovirus and other oncolytic viruses. This is confirmed
in more contemporary patient series and multiple clinical trials. Yet, while the first viruses have already been
granted approval from several regulatory authorities, room for improvement remains.
As good safety and tolerability have been seen, the oncolytic virus field has now moved on to increase efficacy in a
wide array of approaches. Adding different immunomodulatory transgenes to the viruses is one strategy gaining
momentum. Immunostimulatory molecules can thus be produced at the tumor with reduced systemic side effects.
On the other hand, preclinical work suggests additive or synergistic effects with conventional treatments such as
radiotherapy and chemotherapy. In addition, the newly introduced checkpoint inhibitors and other
immunomodulatory drugs could make perfect companions to oncolytic viruses. Especially tumors that seem not to
be recognized by the immune system can be made immunogenic by oncolytic viruses. Logically, the combination
with checkpoint inhibitors is being evaluated in ongoing trials. Another promising avenue is modulating the tumor
microenvironment with oncolytic viruses to allow T cell therapies to work in solid tumors.
Oncolytic viruses could be the next remarkable wave in cancer immunotherapy.
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Background
Cancer is becoming a leading cause of death globally.
Eighteen million new cancers are diagnosed every year
causing almost 10 million deaths (International Agency
for Research on Cancer (IARC), 2019). There has been
significant progress in the prevention and diagnosis of
cancer, but the incidence and mortality are still increas-
ing [1–3]. Conventional therapies, such as surgery,
chemotherapy, hormonal therapies, targeted therapies or
radiation therapy, deliver limited durable responses in a
great majority of patients with advanced cancers [4, 5].
Hematological and testicular malignancies are some of
the few exceptions where current therapies can be cura-
tive even in metastatic cases [6–8].
Cancer is a genetic disease and it represents a range of
manifestations. The principles of tumorigenesis are however
similar across different tumors and relatively well character-
ized. In brief, frequent mutations occur during cell divisions
or due to exogenous factors such as radiation or other
carcinogens. Most of these mutations are corrected by
specialized intracellular proteins. If such mechanisms are un-
successful, mutated cells are generally cleared by apoptosis.
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The vast majority of mutations do not help the cell to gain
cancerous properties (passenger mutations). In contrast,
driver mutations provide exclusive abilities to tumor cells,
such as cell death resistance or metastatic capacity, for ex-
ample [9, 10]. Most of these mutated cells are, however, rec-
ognized by our immune system and destroyed before clinical
detection. Accumulating evidence supports the notion that a
dysfunctional immune system is intimately associated with
tumor development, progression, and recurrence [11]. Also
known as immunosuppression, this phenomenon is actively
propagated by cancer cells either directly or through the
tumor microenvironment [12]. This understanding has gal-
vanized the interest in the development of immunotherapies,
which aims at modifying and activating immune cells to at-
tack cancer cells. The approach is rational as our immune
system has been trained to detect, destroy, and memorize
non-self patterns. By definition, all cancer cells have multiple
mutations causing non-self structures that can potentially be
detected by our immune system [9].
The concept of immunotherapy has been acknowl-
edged already for centuries (Table 1). The relationship
between microbial infections and spontaneous tumor re-
gressions has been reported several times in the litera-
ture [13]. Probably the first evidence was the Ebers
papyrus (1550 BC), one of the oldest and most important
medical documents of ancient Egypt. The physicians of
Egyptian pharaoh Imhotep (2600 BC) used poultice,
followed by incision, for the treatment of tumors. This
facilitated the development of infections which helped to
cause regression of tumors [14]. In 1320, Peregrine
Laziozi was affected by cancer of the tibia requiring
amputation. Unfortunately, local recurrence and pro-
gression were later observed and the tumor finally grew
through his skin causing infection. Later, to everyone’s
astonishment, the tumor disappeared and no relapse was
observed. This phenomenon is today known as the St.
Peregrine tumor [15].
In the seventeenth and eighteenth centuries, various
forms of immunotherapy became widely used. In the
eighteenth and nineteenth centuries, septic dressings
enclosing ulcerative tumors were sometimes used for
cancer treatments. Surgical wounds could be deliberately
left open to enable the development of infection as
purulent infections were suggested helpful [15]. One of
the more detailed case series, indicating several re-
sponses, was reported by surgeon William B. Coley. He
treated cancer patients with a bacterial lysate (heat-killed
Streptococcus pyogenes and Serratia marcescens), also
known as the Coley’s toxin [16].
Reports of viruses having therapeutic benefits in can-
cer started appearing early last century with multiple re-
ports of leukemia patients becoming disease-free after
viral infections [17]. Typically, the reported patients
were young and the remissions were short-lived lasting
for 1 or 2 months [18]. These observations did not go
unnoticed by the medical community, who subsequently
begun utilizing viruses for the treatment of cancer. Espe-
cially during the 1950s and 1960s, multiple wild type
viruses (e.g., hepatitis, Epstein-Barr, West Nile, Uganda,
dengue, yellow fewer) were used to treat different can-
cers in hundreds of case series. Results were variable and
occasionally poorly documented [17]. However, during
this time, it was becoming clear that most wild type vi-
ruses lacked efficacy or safety. Some of the more promis-
ing results with tolerable side effects were associated
with adenoidal-pharyngeal-conjunctival virus [19–22],
nowadays known as the adenovirus. For example, in
1956, 30 women with advanced epidermoid carcinoma
of the cervix were treated with adenovirus. Intra-arterial,
intravenous, and intratumoral administration was used.
Table 1 A timeline including some key steps in development of cancer treatments
Other cancer treatments* Cancer Immunotherapy
Surgery 2600 BCE Use of poultice (pharaoh Imhotep’s physicians)
Surgery under ether anesthesia 1840s CE Purposeful infection of tumors
Radiotherapy 1890s Coley’s toxins (deactivated bacteria) were injected to tumor
Hormonal therapy (estrogen, castration),
chemotherapy (nitrogen mustard, antifolates)
1900–1940s Case reports of tumor regression after natural viral infections
Linear accelerator for radiotherapy,
combination chemotherapy
1950s–1970s Hundreds of case series treating cancer with multiple viruses
(e.g., varicella, measles, vaccinia, West Nile, adenovirus, mumps)
BCG adopted in bladder cancer
Stereotactic radiotherapy, antiestrogens 1980s Adoptive T cell transfer, cytokine therapies (e.g., IFN-alpha and IL-2)
Mini-invasive surgery, monoclonal antibodies
(rituximab, trastuzumab)
1990s HD-IL-2 approved by the FDA
Antiangiogenic therapies (bevacizumab),
kinase inhibitors (imatinib)
2000s First oncolytic adenovirus (H101) approved in China
Small molecular inhibitors of various proteins 2010– Cellular immunotherapy (sipuleucel-T, TCR, CART), six different
checkpoint inhibitors, oncolytic virus (T-vec)
*Many treatments in this column have also immunological properties (e.g., rituximab, trastuzumab, chemotherapy, and radiation therapy)
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Within 10 days, two-thirds of the patients showed ne-
crosis in their tumors and most remarkably, it appeared
to be restricted to the cancerous tissue. No safety prob-
lems were reported in the use of this wild type virus,
suggesting a degree of natural tumor tropism.
Generally, however, virotherapy received little atten-
tion and in the 1970s and 1980s, the regulatory aspects
of clinical trials with living pathogens became stricter. In
turn, chemotherapies, radiation therapy, hormonal ther-
apy, targeted, and antiangiogenic therapies all became
mainstream. It took more than three decades before vi-
ruses re-emerged, this time as “oncolytic viruses” [23,
24]. An oncolytic virus is a virus that infects and lyses
(breaks down) cancer cells but not normal cells. Oncoly-
tic viruses can occur naturally or can be made in the
laboratory by modifying natural viruses. These modifica-
tions started a new era of less toxic cancer targeted
virus-based therapies [25].
Rapid increases in molecular biotechnology techniques
provided means to develop novel strategies to harness
the immune system for cancer therapy. Currently, a
number of approaches, including adoptive cell therapies,
monoclonal antibodies, checkpoint inhibitors, and onco-
lytic viruses constitute the most prominent advance-
ments in cancer treatment due to the capacity to
provide durable and effective clinical responses in cancer
patients [13]. Conventional treatments such as radiation
and chemotherapy treatments also seem to have immu-
nomodulatory effects not recognized before [26, 27].
However, it is essential to note that presently thera-
peutic benefits are restricted to a limited fraction of pa-
tients treated with immunotherapy. In particular, solid
cancers generally contain a suppressive tumor micro-
environment that inhibits T cell activity and supports
tumor progression [28]. In addition, new immunother-
apy treatments have led to the occurrence of new im-
munological adverse events, including cytokine storm
and autoimmune events. Considering these challenges,
further alterations to these therapeutic strategies are
needed. In addition to new immunological treatment
strategies, we also need better understanding of individ-
ual immune environments to provide maximal patient
benefit.
Our aim in this review is to present the current possi-
bilities that oncolytic viruses have to offer. We concen-
trate on adenoviruses that are the most widely studied
virus type. We start by describing general adenovirus
biology and describe then some typical modifications
that can be used to generate better anti-cancer capabil-
ities. Finally, we describe clinical studies with oncolytic
adenoviruses and describe three different types of onco-
lytic viruses that are already regulatory approved to treat
cancer. The aim is to provide a general overview on the
field and we acknowledge that many viral constructs,
especially with preclinical studies only, are not covered.
However, recruiting or completed oncolytic adenovirus
trials (source clinicaltrials.org) give a good general view
of where the field is today. Finally, we conclude by ad-
dressing some future perspectives.
Main text
Structure, function, and immunogenic cell death:
adenovirus as an example
Adenovirus biology has been investigated in detail and it
is well understood. Adenoviruses can be used as an ex-
ample virus when describing oncolytic viruses as a
whole. While there are naturally many differences with
different viruses, many factors are similar to some de-
gree, however not all viruses are naturally oncolytic.
To date, 57 distinct adenovirus serotypes are described
and classified into 7 subgroups: A to G [29, 30]. While
adenoviruses trigger common-flu type infections, these
represent one of the most versatile platforms for cancer
therapy. In particular, serotype 5 (group C) is the most
commonly used backbone for oncolytic virus design
[29]. Its structure encompasses an icosahedral shaped
capsid (composed mainly of hexon, penton, and fiber
proteins) surrounding a non-enveloped double-stranded
DNA [31]. Adenoviruses have the ability to infect cells
independently of their division status.
Infection of tumor cells initiates with the attachment
of the virus fiber knob to receptors located on the sur-
face of tumor cells. This interaction is mediated by dif-
ferent receptors depending on the serotype of the virus.
For example, serotype 5 adenoviruses bind preferentially
to the coxsackie- and adenovirus receptor CXADR [32],
while serotype 3 adenoviruses bind desmoglein-2, CD46
or CD80/86 [33–35]. Some of these receptors are fre-
quently found on cancer cells, while unfortunately some,
such as CXADR, are downregulated in many advanced
tumors [30]. A second interaction between the virus’
penton proteins and tumor cell integrins occurs, result-
ing in virus internalization [36]. Adenoviruses can use
also several other receptors as shown in Table 2. A mul-
tistep process takes the virus DNA into the nucleus,
where transcription of early viral proteins (E1–E4) starts.
Following expression of late proteins, thousands of new
viral progeny emerges, disrupting the cell membrane
after a few days and the newly formed viruses infect new
cells, until the immune system eventually stops this
process [50].
Although not discovered until the treatment of pa-
tients, such cell lysis is a highly immunogenic process
[51]. This factor is of pivotal importance considering
that most cancers seem to be able to hide from our im-
mune system. Immunogenic cell death reveals multiple
tumor-associated antigens for presentation to the im-
mune system via activated mature dendritic cells. High
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numbers of virus genomes activate immunological dan-
ger signaling through damage-associated molecular
pattern (DAMP) and pathogen-associated molecular pat-
tern (PAMP) receptors. These processes form a recipe
that retargets the adaptive immune system, including
cytotoxic CD8+ T cells and helper CD4+ T cells, to-
wards the tumor, thus lifting local immunosuppression
[52]. Of note, anti-adenoviral T cell immunity is poly-
functional rendering increased quality to the overall
ongoing antitumor response [53]. Simultaneously,
adenovirus infection also mediates activation of natural
killer cells further contributing for the antitumor im-
mune response [54]. The generation of antiviral anti-
bodies equally stimulates the response by triggering
antibody-dependent cytotoxicity [55] (Fig. 1).
Modern oncolytic viruses
Today, adenoviruses, herpes viruses, measles viruses,
coxsackie viruses, polioviruses, reoviruses, poxviruses,
and Newcastle disease viruses, among others, are some
of the oncolytic viruses under preclinical and clinical de-
velopment for cancer therapy [56]. Tumor-preferential
replication can be “natural” given the defective viral
sensing mechanisms of most cancer cells [57]. Some of
the cancer cells also harbor increased expression of viral
entry receptors, and some viruses do not appear to need
specific receptors for entry [58]. Abnormal function of
intracellular signaling pathways such as interferon can
be exploited by some viruses [58]. Like many other vi-
ruses, adenoviruses are naturally prone to replicate ag-
gressively in tumor cells and, their wild type versions
could in theory be used in cancer treatments, as was
done in historical series [17, 19–22]. However, better pa-
tient outcomes are expected by rational design of viruses
rendering them tumor selective (“oncolytic”). In recent
years, adenoviruses have been extensively altered to
merge high antitumor potency with minimal toxicity
[25].
Existing molecular biology techniques allow us to (a)
select entry receptors highly expressed on tumors, (b)
refine safety by restricting replication to cancer cells,
and (c) insert specific therapeutic transgenes for in-
creased efficacy. These approaches are discussed below
and summarized in Table 3.
Enhancing tumor tropism
Effective entry of oncolytic viruses into tumor cells is a
prerequisite for subsequent oncolysis. Conversely, low
receptor expression can be a limiting factor. To avoid
the conundrum of low expression of CXADR on tumors
cells, serotype 5 adenoviruses can be modified to contain
arginylglycylaspartic acid (RGD) peptides in their fiber
knobs. Such modification has been shown useful to in-
crease efficacy and reduce the toxicity of adenoviruses
[59, 60]. Clinical implementation of such modified onco-
lytic adenoviruses, such as DNX-2401 (an serotype 5
adenovirus with an RGD modification), has shown
promising results in a phase I clinical study where 20%
of glioma patients showed durable responses [61].
Likewise, replacement of the serotype 5 fiber knob
with one belonging to the serotype 3 has provided sub-
stantial improvements in antitumor efficacy, while
retaining the appealing systemic kinetics and safety of
the ubiquitous serotype 5 [62, 63]. Capsid modification
(e.g., 5/3 chimerism) allows partial overcoming of pre-
existing neutralizing antibodies against Ad5 [72]. Of
note, the antibody question is complex, and in fact base-
line neutralizing antibody titers have not prevented anti-
tumor efficacy in humans [76, 87]. The large amounts of
virus that are produced by tumors into the bloodstream
Table 2 Entry receptors for adenoviruses [37]
Receptor Ligand Reference
Primary receptors
CXADR (coxsackie-adenovirus receptor) Ad5 knob (and other groups A, C, D, E, and F) [38]
CD46 Ad3 knob (and other groups B and D) [39]
Desmoglein-2 Ad3 knob (and other group B) [40, 41]
CD80/CD86 Ad3 knob (and other group B) [33, 37]
Other receptors
Cellular integrins Ad capsid (penton base) or Arg-Gly-Asp (RGD) modifications [42]
Sialic acid Ad 37, 8, 19a (group D) [43]
MHC-I (major histocompatibility complex class I) Ad5 [44]
Vascular adhesion molecule 1 (VCAM-1) Ad5 [45]
Heparan sulfate glycosaminoglycans (HS-GAGs) Ad5 [46]
Dipalmitoyl phosphatidylcholine (DPPC) Ad5 hexon [47]
Blood coagulation factor F(X) Ad 5 hexon [48, 49]
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might simply overcome neutralizing antibodies produ-
cible into blood. In wild type adenovirus infections, only
small amounts of adenovirus enter the blood. Neutraliz-
ing antibodies are designed to block such virus, not the
huge numbers produced by tumors infected with oncoly-
tic virus. Nevertheless, in epidemiological analysis, lack
of antibodies at baseline impacted survival statistically
significantly [76], but not in a clinically meaningful
manner, as responses and long survival could be seen re-
gardless of baseline antibody titers. Interestingly, sequen-
tial intravenous treatments by changing the virus or
serotype might make a difference [88].
As expression of the Ad5 receptor CXADR appears
limiting for efficacy in the context of advanced tumors,
fully serotype 3-based oncolytic adenoviruses have been
constructed [64]. This virus enters through non-
Fig. 1 Activating the immune system for cancer rejection with oncolytic virus therapy. The tumor microenvironment of advanced cancers is
“cold” due to the lack of immunological activity. Oncoytic virus therapy restores the immunological activity of immune tumor infiltrates. a Danger
signal release and DC maturation. Oncolytic adenoviruses infect tumor cells and cause oncolysis, releasing new virus progeny but also DAMPS
and PAMPS, which will activate nearby dendritic cells and foster their maturation by upregulating co-stimulatory markers, such as CD80, CD83,
and CD86. b Mature dendritic cells will process tumor debris and present tumor-associated and virus antigens to local and distant T cells.
Concurrently, the ongoing virus infection attracts T cells to the tumor site. c The activation of B cells by CD4+ T cells or BCR-virus interaction
causes the release of neutralizing antibodies, which mark infected tumor cells for ADCC by NK cells, or phagocytosis by M1 macrophages. d
CD8+ T cells and NK cells destroy infected and non-infected tumor cells through INFg/GranzB and GranzB/Perforins, respectively. The oncolytic
adenovirus infection also upregulates class I HLA in tumor cells, allowing for increased exposure to CD8+ T cells. Overall, the components of this
modulation allow the tumor microenvironment to become “hot” with increased immunological activity. DAMP danger-associated molecular
patterns, PAMP pathogen-associated molecular patterns, HLA human leukocyte antigen, BCR B cell receptor
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CXADR-mediated mechanisms including desmoglein 2,
which is highly expressed in advanced solid tumors [30,
35, 64, 78]. Good safety and signs of efficacy were seen
in patients treated with a fully serotype 3 adenovirus
[64]. Furthermore, a direct evolution method [65] was
used to generate an Ad3/Ad11p chimeric virus which
has been used in multiple trials under the name
ColoAd1 [89].
Safety, restricting replication to cancer cells
To achieve efficient dissemination of input virus and to
minimize virus-related adverse events, adenoviruses have
been modified to achieve increased tumor selectivity.
The strategies employed include transcriptional control
of adenovirus early proteins such as the E1A or E1B. An
E1A gene 24-base pair deletion produces a mutated E1A
protein which cannot bind to the retinoblastoma pro-
tein, thus preventing healthy cells from entering in
synthesis (“S”) phase. This blocks adenovirus DNA repli-
cation in quiescent normal tissues [61, 66]. In contrast,
the replicative potential remains intact in tumor cells
because ubiquitous defects in the p16/Rb pathway en-
sure that cancer cells permanently stay in synthesis
phase [90].
The fact that tumor cells contain several active onco-
genes led to the realization that their resulting proteins
could be harnessed to control transcription of adeno-
virus DNA. For example, telomerase activity is a known
feature of cancer cells, while activity in healthy cells is
minimal [30, 91]. Therefore, adenovirus replication has
been successfully placed under the control of a human
telomerase reverse transcriptase (hTERT) promoter
showing antitumor efficacy in advanced cancers [64, 68].
Similarly, p53 [69], carcinoembryonic antigen (CEA)
[70] and prostate-specific antigen (PSA) [71] have been
utilized to control expression of early adenovirus
proteins. Due to Rb/p16 pathway defects, cancer cells
feature high levels of intracellular free E2F, which can be
used for tumor specificity when the E2F promotor is
inserted to control viral replication [72].
Transgenes, enhancing efficacy
The nature of viruses allows them to hijack the host cell
to produce virus proteins. This allows therapeutic ex-
ploitation with the insertion of therapeutic transgenes
into the adenovirus genome. Before the recognition of
oncolytic adenoviruses as immunotherapy, one of the
most common modifications was the insertion of the
cytosine deaminase and herpes simplex-derived thymi-
dine kinase [74]. The combined administration of
oncolytic adenoviruses with ganciclovir and/or 5-
fluorocytosine (5-FC) prodrugs caused tumor cell death
due to their conversion into cytotoxic compounds by
transduced tumor cells [75].
More recently, the increased recognition of the im-
mune system as an important component in the efficacy
of oncolytic viruses led researchers to perceive oncolytic
adenoviruses as potent vehicles for immune factors.
Adding a granulocyte macrophage colony stimulating
factor (GMCSF) cytokine transgene into the adenoviral
genome is a commonly used modification. In this
approach, virus replication is accompanied by GMCSF
production, which results in the recruitment and matur-
ation of dendritic cells (DCs), and subsequent priming of
T cells with tumor-associated antigens released by onco-
lysis [92]. CGTG-102 (previously Ad5/3-D24-GMCSF,
currently ONCOS-102), is an oncolytic adenovirus ex-
pressing GMCSF. Patient data confirms this notion, with
reported increases in peripheral levels of T cells against
Table 3 Examples of viral modifications in oncolytic
adenoviruses
Modification Reference
Enhancing tumor tropism
RGD modification [59–61]
5/3 chimerism [62, 63]
Fully serotype 3, Ad3/Ad11p [30, 64, 65]
Safety, restricting replication to
cancer cells
E1A gene 24-base pair deletion [61, 66, 67]
hTERT promoter [64, 68]
p53 promoter [69]
CEA promoter [70]
PSA promoter [71]
E2F promotor [72]
Cox2l promoter [73]
Transgenes, enhancing efficacy
Cytosine deaminase and
thymidine kinase
[74]
Ganciclovir and/or
5-fluorocytosine (5-FC) prodrugs
[75]
GMCSF [66, 67, 72, 76, 77]
CD40L [78, 79]
hNIS [80]
TNFalpha and interleukin 2 NCT04217473
CD40L and 41BBL NCT03225989
PH20 hyaluronidase NCT03284268
Anti-CTLA4 [81]
IL-12 and decorin [82]
OX40L [83]
EGFR [84]
FR-a [85]
FAP [10]
CD44v6 [86]
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tumor-associated antigens [66]. These finding suggest
dendritic cell priming in humans as predicted by the
established mechanism of action of GMCSF [93]. The
increased CD8+ T cell infiltration found in tumor biop-
sies after treatment of advanced cancer patients with
ONCOS-102 underlines the immunological potency of
this approach [94]. However, the pleiotropic effects of
GMCSF may endanger antitumor immunity as the cyto-
kine can unwantedly stimulate myeloid-derived suppres-
sor cells (MDSCs) and tumor-associated macrophages
(TAMs), both known to inhibit T cell and natural killer
cell (NK) activity [95]. However, emerging human data
suggests that GMCSF producing viruses might be safe
and effective [76, 77].
Beyond GMCSF, combined expression of IL-12 and
decorin in an oncolytic adenovirus allowed the recovery
of antitumor immunity in a poorly immunogenic murine
breast cancer model, via cytotoxic T cell infiltration and
transforming growth factor beta (TGFb) reduction [82].
Coexpression of CD40L and 4-1BBL by an oncolytic
adenovirus has also shown promising results, due to its
ability to promote the destruction of pancreatic tumors,
through repolarization of the tumor microenvironment.
Such polarization enabled release of T cell attractants
and immune stimulatory cytokines, allowing potent anti-
tumor T cell responses [96]. Production of OX40L
mediated by an oncolytic adenovirus (d24-RGDOX)
promoted increased tumor control via highly functional
effector T cells and epitope spreading [83].
Also, antibodies can be inserted as transgenes to en-
hance the efficacy of oncolytic virotherapy. For example,
anti-CTLA4, a checkpoint inhibitor, has been success-
fully inserted in an oncolytic adenovirus platform. Its
usage in murine models and ex vivo cultures of can-
cer patient peripheral blood mononuclear cells
(PBMCs) resulted in increased antitumor activity of T
cells [81]. More recently, dual targeted antibodies tar-
geting T cells and cancer-specific cell surface antigens
such as epidermal growth factor receptor (EGFR)
[84], FR-a [85], familial adenomatous polyposis (FAP)
[10] and CD44v6 [86], have demonstrated promising
preclinical results [84].
Moreover, also other approaches have been studied.
These include arming with fusogenic molecules, anti-
bodies, T cell engagers, and ion channels capable of con-
centrating radioiodine. While in these cases, the
transgenes are not necessarily immunologically active,
and the oncolytic platform results in immunostimula-
tion. It is important to note that clinical data suggests
that oncolytic adenovirus single-agent efficacy has often
been somewhat limited. Several barriers that affect onco-
lytic adenovirus therapies have been suggested. These in-
clude antiviral interferons, which can be produced by
the tumor stroma even if the cancer cells themselves
lack such ability [50]. Other reasons include stromal bar-
riers, hypoxia, hyperbaric, necrotic, and acidic areas [97,
98]. However, some of these hurdles have been ad-
dressed in redesigned adenoviruses conditionally repli-
cating in response to hypoxic factors or acidic tumor
microenvironments [99].
Alternatively, oncolytic adenoviruses have been armed
with hyaluronidase [100], an enzyme that degrades
hyaluronic acid which hampers virus dissemination.
Notably, treatment of a number of preclinical in vivo
tumor models allowed increased antitumor efficacy.
Neutralizing antibodies remain a concern for oncolytic
immunotherapies. However, the use of bispecific
adapters to retarget antiviral neutralizing antibodies can
offer an attractive approach to increase the effectiveness
of oncolytic adenovirus therapy [101]. The coating of
oncolytic adenoviruses with tumor derivatives has been
reported to allow for successful delivery of particles into
the tumor with potent antitumor responses [102].
Advanced Therapy Access Program (ATAP)
Between 2007 and 2012, 290 advanced cancer patients
were treated with 10 different oncolytic viruses (Table 4)
totaling 821 treatments. A long-term follow-up of these
patients has been published [5]. Treatments were given
in the context of an individualized treatment program
under the EU Advanced Therapies directive [5]. While
many objective responses were seen, no definite conclu-
sions regarding overall survival benefit can be drawn as
no reliable control group was available. However, some
case-control analyses that were performed suggest sur-
vival benefit [88].
While taking into account the limitations of nonran-
domized data, some interesting findings emerged [5, 51,
64, 66, 80, 88, 92, 103, 104, 106]. One of the most im-
portant observations was that all of the administered vi-
ruses appeared quite safe in patients with advanced
cancer. Good tolerability was seen across different sero-
type viruses, including various capsid modifications, and
different immunological arming devices (i.e., GMCSF or
CD40L). Concomitant low-dose cyclophosphamide and
temozolomide were also well tolerated [107]. The former
was used to reduce regulatory T cells. The latter aimed
at increased induction of autophagy in infected cancer
cells, as this appears to be an important mediator of
oncolytic cell death. Moreover, virus replication could be
increased by concomitant calcium channel blockage
[108]. No treatment-related patient deaths were ob-
served [63]. Typical flu-like symptoms, such as fever and
fatigue, were observed in most patients a few days after
treatment. These findings were confirmed in multiple
subsequent clinical trials [61, 94, 109]. Flu-like symp-
toms and fever could be effectively reduced with acet-
aminophen (paracetamol).
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Systemic delivery of oncolytic virus
Biodistribution studies done with adenoviruses in ro-
dents are unreliable as most animals lack entry receptors
or their organ distribution is different from humans.
From ATAP patients, we have been able to collect im-
portant information about virus biodistribution in
humans [63]. Many humans have neutralizing antibodies
against different adenovirus serotypes, although often at
low baseline titer [64]. However, as hundreds of billions
of viruses are given in a typical treatment, pre-existing
antibodies may be unable to completely block intraven-
ous delivery. In subsequent intravenous treatments with
the same serotype, the situation is more unclear, which
is one of the reasons intratumoral delivery is commonly
used with oncolytic viruses. Of note, it has been pro-
posed that antiviral immunity helps generate antitumor
immunity [66].
It has been established in humans that adenovirus is
able to travel through blood to metastases despite neu-
tralizing antibodies [63]. For some viruses, the mechan-
ism appears to relate to binding to blood cells [110].
Interestingly, adenoviruses in blood (qPCR data) were
most often found from blood clots, while some patients
had significant amount of virus in the serum compart-
ment [64]. Also cancer patient’s antibody response var-
ied [64]. Treatment responses or long survival are seen
regardless of neutralizing antibody titers, although it
should be noted that most patients were treated intratu-
morally [76].
Interestingly, we treated seven patients with the sero-
type 3 adenovirus using only intravenous administration.
Signs suggesting virus replication were seen, including
prolonged and/or rising virus titers in the blood. This
was seen also with patients who had pre-existing anti-
bodies against the virus. Also, 5 of the 6 evaluable pa-
tients showed signs of possible benefit. This data
indicates that viruses might be able to enter tumors also
via the intravenous route [64]. This was later confirmed
in an autopsy study where non-injected tumors were
shown to have oncolytic adenovirus [63].
Viruses that have already received regulatory approval
for the treatment of cancer
From a clinical standpoint, the use of viruses for cancer
treatment in the modern era is in its infancy. Initially,
wild type viruses were used, but this approach could re-
sult in adverse events caused by virus replication in nor-
mal tissues. Nevertheless, Rigvir (an ECHO-7 virus)
[111], an oncolytic picornavirus with some innate tumor
selectivity, was the first approved oncolytic virotherapy
product for cancer approved 2004 in Latvia and later in
a few other countries. The second oncolytic virus was
rationally designed for tumor selectivity. Named H101
(Oncorine), this adenovirus has been used in China since
2005 for the treatments of solid tumors [112]. Of note,
both of these viruses lack arming devices.
The acknowledgement that repurposing the immune
system to exert antitumor functions could provide a
promising approach to treat cancer enabled scientists to
employ the immunological capabilities of oncolytic vi-
ruses [113]. For example, the addition of immunological
transgenes such as the GMCSF has been a popular ap-
proach. Talimogene laherparepvec (also known as T-vec,
Imlygic®) is a herpes simplex-1 virus encoding for
GMCSF, and was one of the first oncolytic viruses de-
signed to provide an immunological boost. Its clinical
application eventually led to a randomized phase III clin-
ical trial (OPTiM). In this trial stage IIIB/C and IV meta-
static, unresectable melanoma patients receiving
intratumoral T-vec had a 19.3% durable response rate of
which more than 80% were complete responses [114].
The fact that subcutaneous administration of GM-CSF
Table 4 Viruses used in ATAP
Serotype Main target receptor Tumor specificity Arming
Ad5-D24-GMCSF [92] 5 Coxsackie virus and adenovirus receptor 24 bp deletion in E1A1) GMCSF
Ad5-RGD-D24 [103] 5 Alpha-v-beta integrins 24 bp deletion in E1A1) No
Ad5-RGD-D24-GMCSF [103] 5 Alpha-v-beta integrins 24 bp deletion in E1A1) GMCSF
ICOVIR-7 [104] 5 Alpha-v-beta integrins E2F1 promoter and 24 bp deletion in E1A1) No
Ad5/3-Cox2L-D24 [73] 5 Desmoglein-2 Cox2L promoter and 24 bp deletion in E1A1) No
Ad5/3-D24-GMCSF [88]* 5 Desmoglein-2 24 bp deletion in E1A1) GMCSF
Ad5/3-hTERT-hCD40L [73] 5 Desmoglein-2 hTERT promoter2) CD40L
Ad5/3-E2F1-D24-GMCSF [105] 5 Desmoglein-2 E2F1 promoter and 24 bp deletion in E1A 1) GMCSF
Ad5/3-D24-hNIS [80] 5 Desmoglein-2 24 bp deletion in E1A1) hNIS
Ad3-hTERT-E1A [64] 3 Desmoglein-2 hTERT promoter2) No
*Ad5/3-D24-GMCSF, also known as CGTG-102, and later renamed ONCOS-102, has been subsequently used in several phase 1 and phase 2 clinical
trials (www.targovax.com)
1)Replication in cells with a deficient Rb/p16 pathway (a hallmark of cancer)
2)Replication in cells with active telomerase (a hallmark of cancer)
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offered inferior efficacy (1.4% durable response rate,
0.7% complete response) led to approval by the Food
and Drug Administration (FDA) in 2015, followed by
European Medicines Agency (EMA) [114].
This landmark approval in Western countries encour-
aged optimism in the medical community to continue
developing and improving oncolytic viruses for cancer
therapy, including adenoviruses. Later, in a similar pa-
tient population, pembrolizumab was combined with the
virus leading to responses in 62% of the patients, of
which 33% were complete. As expected, a high presence
of cytotoxic T cell infiltration was observed in the tu-
mors following treatment [115]. A recent phase II clin-
ical trial in advanced melanoma patients demonstrated
that T-vec increased the response rate of ipilimumab as
compared to ipilimumab alone (38% vs 18%, respect-
ively) [116]. Of note, and in contrast to combinations of
checkpoint inhibitors [117], adverse events were not
compounded. This suggests that oncolytic viruses can be
combined with checkpoint inhibition without a problem-
atic decrease in safety.
Oncolytic adenovirus trials
At the time of writing this review (March 2020), we did
a search on clinicaltrials.org, resulting in 101 trial re-
sults. Limiting the search to “oncolytic adenovirus”
phases I–II trials, we came up with 41 results; of these,
10 were completed and 15 recruiting. Sixteen different
oncolytic viruses were used in these completed or
recruiting trials. No active phase III clinical trials were
found. Interestingly, 6 out of the 16 viruses have been
posted recently, during 2019–2020, indicating growing
interest and available funding for oncolytic adenovirus
trials (Table 5).
Use of oncolytic viruses in hematologic malignancies
Observations of hematological cancer regressions follow-
ing virus infection were seen early last century [17, 18].
Of note, response evaluation was possible for
hematological malignancies, by microscopy and cell
counting, while this was not true for most solid tumors
at the time. This might have caused overrepresentation
of hematological cancer in early literature, due to obser-
vational bias. However, it cannot be denied that many
reports suggested regression of hematological tumors
after viral infections. As such, there is strong rationale to
believe that oncolytic viruses could be used also in
hematological malignancies. However, not all viruses are
suitable for treatment of blood cell tumors. For example,
adenovirus does not appear to be able to lyse white
blood cells [118].
According to recent publications, growing interest to-
wards oncolytic viruses is present also in the
hematological field, as several viruses are being studied
in preclinical settings [119]. However, only a few trials
have been published [120]. A search from clinicaltrials.
gov did not reveal any results for trials on “hematologic
neoplasm” and “oncolytic viruses” (March 2020). How-
ever, a search for “multiple myeloma” and “oncolytic vi-
ruses” found two studies.
To conclude, to date, there have been few trials with
oncolytic viruses in hematological cancers. Some note-
worthy efforts include early phase trials with reovirus
[121], measles [122], and vesicular stomatitis virus (VSV)
in multiple myeloma [120]. The currently recruiting
VSV trial (NCT03017820) also includes patients with re-
lapsed acute myeloid leukemia and T cell lymphoma. No
hematological trials with oncolytic adenovirus were
found.
Limitations and newer strategies to improve efficacy of
oncolytic viruses
Arming with immunostimulatory cytokines has been
one popular method to generate immunological syn-
ergy with the effects of oncolysis. Clinical benefit of
this approach was seen in the phase III OPTiM trial
where 1 in 6 patients achieved complete responses
with the oncolytic virus talimogene laherparepvec.
The median duration of these complete responses in
the virus group was not reached and 8 out of 9 pa-
tients survived over 5 years [114].
Combining oncolytic viruses with T cell activating
checkpoint inhibition can improve antitumor efficacy of
oncolytic adenovirus therapy. Especially tumors with low
amount of immunological cells—“cold tumors”—can be
efficiently immune activated by oncolytic adenoviruses.
This makes tumors “hot” and promotes the effects of
checkpoint inhibitors [94, 123]. Clinical proof-of-
concept for the efficacy of combining oncolytic viruses
with checkpoint inhibitors has been presented [116,
124]. In a randomized phase II study (n = 198) a check-
point inhibitor (ipilimumab) was combined with the
oncolytic virus talimogene laherparepvec, showing ob-
jective responses in 39% of the patients, compared to
18% in the checkpoint inhibitor-only arm [116, 125].
In addition to melanoma, recent publications suggest
clinical activity also in other cancers such as metastatic
sarcoma where the same combination resulted in a 30%
objective response rate in a single-arm trial [126]. Fur-
thermore, the safety profile of these treatments has been
good and oncolytic viruses do not seem to increase the
rate of serious adverse events.
Although these combinations seem to yield increased
potency and long-term benefits to some patients, not all
benefit, and there is clearly a role for further improve-
ment. Combining chemotherapy or radiation therapy in
a rational way to improve treatment benefits, and even
these conventional therapies seem to have an
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Table 5 Sixteen oncolytic adenoviruses used in phase I–II trials that have been completed or recruiting (Mar-2020 clinicaltrials.org).
First
posted
Last
update
Oncolytic
adenovirus
(transgene)
Study title(s) Indication(s) NCT# identifier
2012 2019 ONCOS-102a
(GMCSF)
Completed: ONCOS-102 (Previously CGTG-102) for Therapy of Advanced
Cancers
Recruiting: (1) A Pilot Study of Sequential ONCOS-102, an Engineered
Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients
With Advanced or Unresectable Melanoma Progressing After Pro-
grammed Cell Death Protein 1 (PD1) Blockade (2) A Phase I/II, Safety
Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic
Castration-resistant Prostate Cancer
Solid tumors,
melanoma, and
prostate cancer
NCT03003676,
NCT03514836
2012 2015 Delta-24-rgd Completed: Safety Study of Replication-competent Adenovirus (Delta-
24-rgd) in Patients With Recurrent Glioblastoma
Glioblastoma NCT01582516
2013 2020 DNX-2401b Completed: (1) Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrin-
sic Pontine Gliomas (2) DNX-2401 With Interferon Gamma (IFN-γ) for Re-
current Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I) (3) Virus
DNX2401 and Temozolomide in Recurrent Glioblastoma (D24GBM)
Recruiting: Oncolytic Adenovirus DNX-2401 in Treating Patients With Re-
current High-Grade Glioma
Gliomas NCT03178032,
NCT02197169,
NCT01956734,
NCT03896568
2013 2016 CELYVIR Completed: Safety and Efficacy of Repeated Infusion of CELYVIR in
Children and Adults With Metastatic and Refractory Tumors.
Solid tumors NCT01844661
2013 2017 ICOVIR-5 Completed: Phase I Endovenous Administration of Oncolytic Adenovirus
ICOVIR-5 in Patients With Advanced or Metastatic Melanoma
Melanoma NCT01864759
2014 2019 VCN-01 (PH20
hyaluronidase)
Completed: A phase I Dose Escalation Study of Intratumoral VCN-01 In-
jections With Gemcitabine and Abraxane in Patients With Advanced
Pancreatic Cancer
Recruiting: Safety, Tolerability, and Efficacy of VCN-01 With Durvalumab
in R/M Head and Neck Squamous Cell Carcinoma
Pancreatic cancer
and head and neck
NCT03284268,
NCT03799744
2014 2020 ColoAd1c Completed: Mechanism of Action Trial of ColoAd1 (MOA)
Recruiting: Chemoradiation With Enadenotucirev as a Radiosensitiser in
Locally Advanced Rectal Cancer (CEDAR)
Colon, non-small cell
lung, bladder, and
renal cell
NCT02053220
2015 2019 CG0070
(GMCSF)
Completed: Safety and Efficacy of CG0070 Oncolytic Virus Regimen for
High Grade NMIBC After BCG Failure (BOND2)
Superficial bladder
cancer
NCT02365818
2020 2020 TILT-123d
(TNFalpha and
IL-2)
Recruiting: TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus
TILT-123 During TIL Treatment of Advanced Melanoma
Melanoma NCT04217473
2016 2020 LOAd703
(CD40L and
41BBL)
Recruiting: (1) Trial Investigating an Immunostimulatory Oncolytic
Adenovirus for Cancer (2) LOAd703 Oncolytic Virus Therapy for
Pancreatic Cancer (3) A Phase I/II Trial Investigating LOAd703 in
Combination With Atezolizumab in Malignant Melanoma
Pancreatic, ovarian,
biliary, colorectal, and
melanoma
NCT03225989,
NCT02705196,
NCT04123470
2019 2020 ORCA-010 Recruiting: First in Man Clinical Study to Evaluate Safety and Tolerability
of an Oncolytic Adenovirus in Prostate Cancer Patients.
Prostate cancer NCT04097002
2017 2017 Ad5-yCD/
mutTKSR39rep-
hIL12 (IL-12)
Recruiting: Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic
Pancreatic Cancer
Pancreatic cancer NCT03281382
2017 2019 NSC-CRAd-
Survivin-pk7
Recruiting: Neural Stem Cell Based Virotherapy of Newly Diagnosed
Malignant Glioma (neural stem cells loaded with NSC-CRAd-Survivin-
pk7)
Glioma NCT03072134
2019 2020 NG-641 (CXCL9/
CXCL10/IFNα)
Recruiting: First in Human Study With NG-641, an Oncolytic Transgene
Expressing Adenoviral Vector
FAP-TAc antibody together with an immune enhancer module (CXCL9/
CXCL10/IFNα).
Epithelial tumors NCT04053283
2016 2019 ADV/HSV-tk
(HSV-tk)
Recruiting: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for
Metastatic TNBC and NSCLC (STOMP)
Breast and lung NCT03004183
2019 2020 NG-350A (anti-
CD40 ab)
Recruiting: First in Human Study of NG-350A (an Oncolytic Adenoviral
Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE)
Epithelial tumors NCT03852511
aONCOS-102 was previously used in our ATAP treatment series as Ad5/3-D24-GMCSF and CGTG-102 [88]
bPreviously known as Delta-24-rgd
cAlso knowns as enadenotucirev
dTILT-123 is a double-armed virus designed for activation of T cells. It was designed based on human data from ATAP
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immunological component [27, 127]. However, clear
clinical proof in support of this approach is currently
limited.
Combining other therapies such as adoptive cell ther-
apy or targeted therapies might also result in better
treatments. However, we are still lacking much informa-
tion about the immune effects in individual tumors. This
insufficiency of knowledge makes it hard to understand
which patients would benefit most of what kind of treat-
ment combinations. This could be the greatest challenge
in the field at the moment. Classic trial design is not well
suited for understanding mechanisms on an individual
tumor and patient level.
TILT-123 studies
An ideal cancer treatment should be so good that most
patients would clearly benefit while side effects should
be tolerable. Our own contribution to this quest is a
novel oncolytic adenovirus, designed specifically with T
cells in mind. Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-
123) is based on the well understood and safe adenovirus
serotype 5, but its fiber knob has been changed to a
serotype 3 knob for enhanced penetrance to tumor cells
[128]. The replication of the virus is strictly limited to
cancer cells by dual control (E2F promoter and D24 de-
letion) and the potency of the virus is optimized by two
transgenes, which were selected in a data-driven manner
[95, 129]. Chimeric 5/3 adenoviruses also represent the
best native T cell stimulator, among clinically relevant
oncolytic adenoviruses [130].
The combination that emerged as the best approach
for recruiting and activating T cells was interleukin-2
(IL-2) and tumor necrosis factor alpha (TNFa) [129]. IL-
2 is required for T cell growth and survival and TNFa is
a potent inducer of T cell trafficking and tumor
apoptosis [129, 131–133]. In preclinical models, admin-
istration of cytokine-coding adenoviruses increased the
antitumor efficacy of three forms of adoptive T cell
therapy: T cell receptor (TCR)-engineered T cells [129],
CAR T cell therapy [134], and tumor-infiltrating
lymphocyte (TIL) therapy [128, 135].
This outcome resulted from the following: (1) im-
proved infiltration of transferred cells induced by TNFa,
(2) improved activity of cytotoxic T cells induced by IL-
2, and (3) overall decrease of immune suppressive sub-
sets including regulatory T cells (Tregs), MDSCs, and
M2 macrophages in the tumor microenvironment [129].
Hamsters bearing pancreatic tumors treated with TILT-
123 showed signs of improved antitumor efficacy as
compared to animals receiving TIL therapy or TILT-123
alone [128]. Combination of IL-2 and TNFa coding ade-
noviruses and anti-PD-1 therapy also fostered long-term
100% survival in preclinical models bearing a melanoma
tumor model [136].
Further studies with the virus demonstrated abscopal
effect in non-injected tumors, showing the systemic na-
ture of the immune response generated by local treat-
ment [128]. Moreover, TILT-123 therapy in TIL-treated
animals demonstrated protective immunity towards
tumor re-challenge [128]. Importantly, this data demon-
strates the potential of TILT-123 to fine-tune and over-
come challenges of T cell-based adoptive cell therapy.
The first trial with this advanced oncolytic adenovirus is
now ongoing (NCT04217473).
Conclusions
In summary, while preclinical data for oncolytic adenovi-
ruses is impressive and clinical data have shown efficacy,
more potent treatment strategies are needed to achieve
long-term tumor control in patients. Thus, it is logical
that several approaches are being utilized for improving
the efficacy of oncolytic viruses. Hopefully, the efforts of
the scientific and medical communities during multiple
decades will lead to better treatment options in the near
future. Better understanding of individual patient-tumor
immune status will likely emerge and we will be able to
treat advanced cancer patients better. It appears that
oncolytic viruses will be part of future multimodality ap-
proaches. New treatments are urgently needed to help
the 10 million cancer patients that are dying each year.
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